title: Does dexmedetomidine provide cardioprotection in coronary artery bypass grafting with cardiopulmonary bypass? A pilot study.
abstract: OBJECTIVE
  The purpose of this pilot study was to evaluate whether dexmedetomidine has a cardioprotective effect during coronary artery bypass graft surgery with cardiopulmonary bypass (CPB).
  
  
  METHODS
  A prospective, double-blind, randomized controlled trial.
  
  
  METHODS
  A university hospital.
  
  
  METHODS
  Thirty-eight patients undergoing coronary artery bypass graft surgery.
  
  
  METHODS
  Patients were randomized into 2 groups: dexmedetomidine and placebo groups. In the dexmedetomidine group, dexmedetomidine infusion was started by a loading dose of 0.5 μg/kg/10 min, followed by a continuous infusion of 0.5 μg/kg/h. The placebo group received the same volume of saline. Measurements of central venous pressure, mean pulmonary artery pressure (MPAP) and cardiac index were performed before and after dexmedetomidine loading dose and 2, 24 and 48 hours after CPB. Simultaneously, arterial blood was sampled for CK-MB, cardiac troponin T, and N-terminal probrain natriuretic peptide.
  
  
  RESULTS
  CK-MB, cardiac troponin T and N-terminal probrain natriuretic peptide values were elevated in the periods after CPB in both groups (p<0.05) and there were no statistically significant differences between groups. MPAP was decreased in the dexmedetomidine group at the 2nd, 24th and 48th hour after CPB (p<0.001, p<0.001, p = 0.002, respectively). Higher cardiac index values were seen earlier in the dexmedetomidine group than in the placebo group (p< 0.05).
  
  
  CONCLUSIONS
  Myocardial damage was not reduced by administration of 0.5 μg/kg loading dose and 0.5 μg/kg/h infusion of dexmedetomidine. However MPAP tended to be lower in the dexmedetomidine group. Large-scale clinical outcome studies are indicated to confirm the effect of dexmedetomidine.
authors.affiliation: Department of Anesthesiology and Reanimation, University of Erciyes, School of Medicine, Talas, Kayseri, Turkey. zeynept@erciyes.edu.tr
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Tosun
authors.forename: Mehmet
authors.initials: M
authors.lastname: Baktir
authors.forename: Husnu Cemal
authors.initials: HC
authors.lastname: Kahraman
authors.forename: Gulden
authors.initials: G
authors.lastname: Baskol
authors.forename: Gulen
authors.initials: G
authors.lastname: Guler
authors.forename: Adem
authors.initials: A
authors.lastname: Boyaci
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001794:Blood Pressure / Q000187:drug effects; D002316:Cardiotonic Agents / Q000627:therapeutic use; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D052279:Creatine Kinase, MB Form / Q000097:blood; D020927:Dexmedetomidine / Q000627:therapeutic use*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D010865:Pilot Projects; D011229:Preanesthetic Medication; D020107:Troponin T / Q000097:blood
chemical_list: D002316:Cardiotonic Agents; D006993:Hypnotics and Sedatives; D010446:Peptide Fragments; D020107:Troponin T; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D020927:Dexmedetomidine; D052279:Creatine Kinase, MB Form
keywords: cardioprotective effect; cardiopulmonary bypass; coronary artery bypass grafting; dexmedetomidine